ReST Therapeutics is a Clinical Biotech leveraging its successful Seed Funding to advance our proprietary drug candidate through non-clinical testing and achieve the First in Human clinical study.
Latest News
EMA endorses ReST FIH for FENM
ReST Therapeutics announces the endorsement by the European Medicine Agency (EMA) to enter the clinical phase and request First in Human (FIH) administration of its drug candidate FENM. ReST Therapeutics, clinical-stage biotech company developing breakthrough...
First Results on FENM published in International Journal of Neuropsychopharmacology
FENM appeared as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses.
Pr. John Krystal joins ReST SAB
ReST Therapeutics announces that Pr. John Krystal has joined its Scientific Advisory Board ReST Therapeutics, clinical-stage biotech company developing breakthrough therapies to treat Alzheimer Disease (AD) and Post-Traumatic Stress Disorder (PTSD), today announced...
USPTO grants ReST Therapeutic’s Patent on PTSD
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST Therapeutics' project is to develop a proprietary drug candidate for the treatment of Post-Traumatic Syndrome and...
A new patent for Biotech ReST Therapeutics as part of its search for solutions against Post-Traumatic Syndrome and Alzheimer’s
On May 6, the National Institute of Intellectual Property (INPI) issued ReST Therapeutics and its academic co-owners (University of Montpellier, INSERM, and the Ecole Pratique des Hautes Etudes) a patent on neuroprotection. ReST Therapeutics' project is to develop a...
FENM for the prevention and treatment of stress-induced maladaptive behavior
Biological Psychiatry Published: May 09, 2021DOI: https://doi.org/10.1016/j.biopsych.2021.04.024 Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior....
FENM facilitates extinction learning without sensorimotor deficits
International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning WithoutSensorimotor Deficits. Briana K. Chen, Gwenaëlle Le Pen,...
ReST Results on Alzheimer to be presented at AD/PD 2021
Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases